Current Opinion in Hematology volume 17, issue 4, P276-280 2010 DOI: 10.1097/moh.0b013e328339f2ee View full text
|
|
Share
Hongyan Zhou, Sheng Ding

Abstract: iPSC technology provides unprecedented opportunities in biomedical research and regenerative medicine. However, there remain a great deal to learn about iPSC safety, the reprogramming mechanisms, and better ways to direct a specific reprogramming process. The iPSC field will flourish on its mechanistic studies, iPSC-based disease modeling, and identification of new small molecules that modulate reprogramming.